Patients must have histologically confirmed ER+ and/or PR+, HER-, early invasive breast cancer.
Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically confirmed HER-negative localized breast cancer by core biopsy.
Primary operable, non-metastatic invasive carcinoma of the breast, confirmed histologically by core biopsy.
Participants must have histologically or cytologically confirmed invasive breast cancer
Patients must have histologically confirmed new diagnosis of breast cancer
Histologically confirmed invasive cancer of the breast
have a histologically confirmed diagnosis of ER+ breast cancer;
Histologically confirmed diagnosis of invasive breast cancer
Diagnosis of histologically confirmed invasive primary rectal carcinoma
Histologically proven invasive adenocarcinoma of breast
Histologically-confirmed, primary, invasive breast cancer diagnosed within  years of study entry
Patients with histologically confirmed intact primary cancer that is confirmed invasive carcinoma of the breast, with at least . cm residual disease as measured by mammography, ultrasound, or breast magnetic resonance imaging (MRI) after neoadjuvant anthracycline based chemotherapy
Subjects have histologically confirmed adenocarcinoma of the breast - all breast cancer subtypes are allowed
Histologically confirmed breast cancer
Newly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT or T, N-, and M
Histologically confirmed diagnosis of invasive breast cancer
Histologically confirmed diagnosis of invasive breast cancer
Newly diagnosed histologically confirmed invasive breast cancer
Histologically confirmed HER-positive metastatic breast cancer
Histologically confirmed diagnosis of invasive or non-invasive breast cancer
Histologically confirmed diagnosis of invasive cervical cancer
Histologically confirmed invasive primary breast cancer
Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically confirmed invasive breast cancer
Female with histologically confirmed breast cancer
Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
Histologically confirmed unilateral or bilateral primary invasive carcinoma of the breast.
Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>)  cm
Non-metastatic operable primary invasive HER-positive carcinoma of the breast that is histologically confirmed, and adequately excised
Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.
Patients must have histologically confirmed invasive breast cancer with a primary tumor >=  cm in greatest dimension as measured by clinical or radiologic examination
Postmenopausal women with histologically or cytologically confirmed invasive, ER+/HER- (defined by local guidelines) metastatic or inoperable, locally advance breast cancer
History of histologically-confirmed bilateral breast cancer
Patients must have a histologically confirmed diagnosis of hormone receptor positive, HER negative invasive breast carcinoma
Histologically or cytologically confirmed invasive breast cancer with distant metastasis
PHASE II: Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Non-metastatic histologically confirmed primary invasive breast carcinoma that was operable
Participants must have histologically confirmed HER+ (+ by immunohistochemistry and/or FISH ratio >= .) invasive breast cancer; central confirmation of HER status is not required
Histologically confirmed invasive cancer of the breast.
Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible
Histologically confirmed invasive breast carcinoma
Histologically confirmed Stage I to III invasive breast cancer. Subjects may have more than one synchronous primary breast tumor.
Patients must have histologically or cytologically confirmed invasive cancer of the breast
Histologically confirmed primary invasive adenocarcinoma of the breast
Histologically or cytologically confirmed invasive breast carcinoma at local institution
Have histologically confirmed breast or ovarian carcinoma
Histologically or cytologically confirmed invasive carcinoma of the breast
Histologically or cytologically confirmed invasive breast carcinoma
Histologically or cytologically confirmed HER-positive invasive breast cancer, with Stage IV disease;
Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
Women histologically diagnosed with carcinoma of the breast
Patients must have evidence of histologically confirmed invasive breast cancer, stage I, II or III, and be at least  years post diagnosis
Histologically confirmed carcinoma of the breast
Non-metastatic histologically confirmed primary invasive breast carcinoma
Patients must be women with histologically confirmed primary invasive carcinoma of the breast (stage I, II, or III) with no evidence of metastatic disease (M) or with histologically confirmed ductal carcinoma in situ (DCIS); if patient has undergone breast cancer surgery, she must have recovered from all side-effects of surgery
Patients with histologically confirmed invasive breast cancer, stage I - IV, treated at Lyndon B. Johnson General Hospital in the Harris Health System
Prior history of histologically confirmed bilateral invasive breast cancer
A history of histologically-confirmed bilateral invasive breast cancer
Histologically confirmed metastatic breast cancer
Have a histologically-confirmed diagnosis of breast cancer
Histologically confirmed cT-, N breast cancer
Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast
Group I: Diagnosis of histologically confirmed invasive breast cancer
Group II: Diagnosis of histologically confirmed invasive breast cancer
Women with histologically proven invasive breast cancer and no distant metastases and;
Patients must have histologically confirmed invasive breast cancer